Kawin Technology(SH:688687) Xin Lang Cai Jing·2026-02-27 08:21Group 1 - The company reported a total operating revenue of 1.321 billion yuan for the fiscal year 2025, representing a year-on-year increase of 7.35% [1] - The net profit for the same period was 29.6312 million yuan, showing a significant year-on-year decline of 79.19% [1] - The company made a substantial asset impairment provision during the reporting period [1] Group 2 - The company decided to voluntarily withdraw the drug registration application for Pegylated Interferon α-2 Injection (new hepatitis B indication) based on the latest review suggestions from the National Medical Products Administration [1] - As a result of this decision, the company fully provided for the asset impairment related to the remaining development expenses of this project [1]